Through a sample of saliva the genetic test called Onco Life Test It allows knowing the predisposition that a person has to suffer from some type of hereditary cancer such as breast, ovarian, prostate, pancreas, colon, gastric, uterus and melanoma.
This condition is caused by mutations or deficiencies in the genes, in the case of sporadic cancers (without a family history), the mutations develop throughout life, while in hereditary cancer they are transmitted in a generational manner.
According to American Cancer Society, it is estimated that around 5 to 10 percent of all cancer cases are related to inheritance. It should be noted that inheriting the gene does not mean that the person is destined to have cancer irremediably, the only thing that means is that you have a greater risk of developing the disease.
This predictive genetic test analyzes 30 genes associated with hereditary cancer through saliva. With the results, a “level of genetic risk” is obtained, in this way, the patient with the help of a specialist doctor can adopt the necessary preventive measures in order to reduce the risk of developing the disease.
Includes next generation massive sequencing (NGS: Next Generation Sequencing) and an advanced bioinformatic analysis, which can accurately determine the hereditary risk of cancer.
Through Grupo SOHIN the test is available in Mexico. It is a company specialized in genomic medicine and comprehensive health services in Mexico, dedicated to personalized medicine in patients with chronic degenerative diseases such as cancer.
“At SOHIN we are convinced that genetic medicine is a key ally to face the current public health challenges. Thanks to technological advances, today we have high precision diagnoses that allow us to prevent chronic degenerative diseases even before they appear, putting us one step ahead, “said Juana Ramírez, CEO and founder of Grupo SOHIN.
It is necessary to resort to a specialist doctor to practice this test if one or more relatives of the first degree (mother, son, brother or father) have presented cancer before the age of 50. The ideal is to take an assessment 10 years before the age when the youngest case in the family was presented.